Pharmacological effects of phosphatidylserine liposomes

Bruni, A.; Toffano, G.; Leon, Alberta; Boarato, E.

doi:10.1038/260331a0

Cited by 92 publications

(29 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effect of phosphatidylserine liposomes under these conditions is described in this paper. Since phosphatidylserine administration is accompanied by efflux of adrenaline from the adrenal medulla (Bruni et al, 1976b), experiments have been carried out with adrenaline in order to distinguish between the catecholamine-mediated and the direct effect of phospholipid. An additional control is provided by the administration of a concentrated solution of glucose in an amount sufficient to increase the © Macmillan Journals Ltd 1979 blood and brain levels in the absence of other pharmacological stimuli.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacological Effects of Phosphatidylserine Liposomes: Regulation of Glycolysis and Energy Level in Brain

Bigon¹,

Boarato²,

Bruni³

et al. 1979

British J Pharmacology

Self Cite

View full text Add to dashboard Cite

I The accumulation of glucose in the brain produced by the administration of phosphatidylserine liposomes into mice has been studied by measurement of the cerebral contents of glycolytic intermediates and high-energy compounds. 2 With a normal supply of oxygen to the brain, inhibition of glycolysis is indicated mainly at the phosphofructokinase step. The ratio of glucose-6-phosphate to fructose-1,6-diphosphate increased. whereas the levels of pyruvate and especially lactate decreased. 3 Under conditions of cerebral ischaemia, the administration of phosphatidylserine delays glycogen mobilization and ATP use. As a consequence of decreased energy utilization, the brain adenylate energy charge remains at a high level. 4 It is concluded that the phosphatidylserine-induced glucose accumulation in the brain is due to reduced energy expenditure and therefore to a decrease in carbohydrate consumption. The inhibition of glycolysis by the high level of adenylate energy charge is probably the control mechanism explaining the decreased carbohydrate utilization.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Previous studies (Bruni, Leon & Boarato, 1976a;Bruni, Toffano, Leon & Boarato, 1976b) have shown that mixed brain phospholipids produce hyperglycaemia and accumulation of glucose in the brain. Phosphatidylserine alone reproduces these effects.…”

Section: Introductionmentioning

confidence: 99%

Pharmacological Effects of Phosphatidylserine Liposomes: Regulation of Glycolysis and Energy Level in Brain

Bigon¹,

Boarato²,

Bruni³

et al. 1979

British J Pharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Other investigators have also used liposomes containing a 7:2:1 molar ratio of egg phosphatidylcholine, cholesterol and phosphatidic acid without any observable toxic effects in rats (Gregoriadis, 1976) or man (Gregoriadis et al, 1974;Tyrrell et al, 1976;Belchetz et al, 1977). However, some lipid compositions used in making liposomes have had toxic side effects (Bruni et al, 1976;Adams et al, 1977;Steger & Desnick, 1977). Animal tumour studies have shown that very small negatively charged liposomes appear to concentrate well in tumour tissue (Richardson et al, 1978a).…”

mentioning

confidence: 99%

Tissue distribution and tumour localization of 99m-technetium-labelled liposomes in cancer patients

Richardson¹,

Ryman²,

Jewkes³

et al. 1979

Br J Cancer

View full text Add to dashboard Cite

The possible use of liposomes (phospholipid vesicles) to direct cytotoxic drugs to tumours has led us to investigate the tissue localization of i.v. injected 99m-Tc-labelled liposomes in cancer patients. Twenty mg or 300 mg doses of liposomal lipid (7:2:1 molar ratio of phosphatidylcholine : cholesterol : phosphatidic acid) were used in a study of 13 patients with advanced cancer and one with polycythaemia rubra vera (PRV). In all cases except the patient with PRV the major site of uptake of the label was the liver and spleen. In the patient with PRV the liver uptake was greatly reduced and the major site of uptake was found in regions corresponding to marrow. With the exception of one patient with a primary hepatoma, there was no significant tumour uptake of the label. Images Fig. 2 Fig. 3

show abstract

“…This also necessitated the use of the free drug plus empty liposome control. (Tyrrell et al, 1977;Layton et al, 1980;Campbell, 1980) and in vivo (Bruni et al, 1976;De Barsey et al, 1976;Adams et al, 1977;Steger & Desnick, 1977). Liposome toxicity must be considered when making any measurements involving the use of liposomes.…”

mentioning

confidence: 99%

Liposomally trapped AraCTP to overcome AraC resistance in a murine lymphoma in vitro

Richardson¹,

Curt²,

Ryman³

1982

Br J Cancer

View full text Add to dashboard Cite

show abstract

Pharmacological effects of phosphatidylserine liposomes

Cited by 92 publications

References 18 publications

Pharmacological Effects of Phosphatidylserine Liposomes: Regulation of Glycolysis and Energy Level in Brain

Pharmacological Effects of Phosphatidylserine Liposomes: Regulation of Glycolysis and Energy Level in Brain

Tissue distribution and tumour localization of 99m-technetium-labelled liposomes in cancer patients

Liposomally trapped AraCTP to overcome AraC resistance in a murine lymphoma in vitro

Contact Info

Product

Resources

About